.jpg "Cryolife (NYSE: CRY)")
Today, the SVP, Global Sales of Cryolife (NYSE: CRY), Davis John, bought shares of CRY for $44.78K.
Following this transaction Davis John E’s holding in the company was increased by 8.5% to a total of $1.31 million. In addition to Davis John, 6 other CRY executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $61.95 million and GAAP net loss of $3.82 million. In comparison, last year the company earned revenue of $45.06 million and had a net profit of $2.18 million. Currently, Cryolife has an average volume of 428.2K.
Starting in April 2016, CRY received 45 Buy ratings in a row. Four different firms, including Canaccord Genuity and Northland Securities, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $1.13M worth of CRY shares and purchased $44.78K worth of CRY shares. The insider sentiment on Cryolife has been negative according to 66 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
